FDA will publicly scold drug companies that try to derail generics
The FDA’s new tactic for driving down prescription drug costs: publicly shaming them by “shining a light on situations where drug makers may be pursuing gaming tactics to delay generic competition.” Drug companies that try to scuttle generic competition will be named on the FDA’s Website.
Related articles
-
ArticleDOJ dismisses indictment against Cassava advisor amid legal flaws
The DOJ dropped a June 2024 indictment against a Cassava Sciences advisor, closing a case tied to an alleged short-selling scheme and related government probes. The case was criticized for fundamental flaws in evidence and legal procedures.
-
ArticleNavigating HHS and FDA’s overhaul of the food and beverage industry
Under the Trump administration, the Department of Health and Human Services and the Food and Drug Administration have been hellbent on eliminating synthetic food dyes from food and beverage products, forcing a jarring and costly overhaul with cascading impacts on the operations of the entire industry.
-
News BriefCommunication and relationships is increasingly critical for compliance teams
Compliance is increasingly in the spotlight as companies are tackling everything from artificial intelligence and other new technologies to risk management and mitigation. But it’s soft skills of communication and relationship building that are becoming the most critical tools for success.